Michael Webster-Clark
Overview
Explore the profile of Michael Webster-Clark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Webster-Clark M, Matthews A, Ellis A, Kinlaw A, Platt R
J Clin Epidemiol
. 2025 Feb;
181:111716.
PMID: 39924128
Objectives: While subgroup analyses are common in epidemiologic research, restriction to subgroup members can yield imprecise estimates. We aimed to demonstrate how methods extending inferences to external targets improve precision...
2.
Her Q, Rouette J, Young J, Webster-Clark M, Tazare J
Pharmacoepidemiol Drug Saf
. 2024 Nov;
33(12):e70048.
PMID: 39586646
In this article, we review the history and key reasons for new-user comparisons in pharmacoepidemiology, highlighting the target trial framework as a unifying framework. We describe three distinct pharmacoepidemiological new-user...
3.
Webster-Clark M, Ross R, Keil A, Platt R
Am J Epidemiol
. 2024 Apr;
193(8):1176-1181.
PMID: 38629587
External validity is an important part of epidemiologic research. To validly estimate effects in specific external target populations using a chosen effect measure (ie, "transport"), some methods require that one...
4.
Young J, Webster-Clark M, Shmuel S, Garry E, Mavros P, Sturmer T, et al.
Pharmacoepidemiol Drug Saf
. 2024 Apr;
33(4):e5790.
PMID: 38575389
Purpose: The prevalent new user design extends the active comparator new user design to include patients switching to a treatment of interest from a comparator. We examined the impact of...
5.
Webster-Clark M, Filion K, Platt R
Am J Epidemiol
. 2024 Feb;
193(7):1031-1039.
PMID: 38412261
Distributed network studies and multisite studies assess drug safety and effectiveness in diverse populations by pooling information. Targeting groups of clinical or policy interest (including specific sites or site combinations)...
6.
Webster-Clark M, Toh S, Arnold J, McTigue K, Carton T, Platt R
Pharmacoepidemiol Drug Saf
. 2023 Jul;
32(12):1360-1367.
PMID: 37463756
Purpose: While much has been written about how distributed networks address internal validity, external validity is rarely discussed. We aimed to define key terms related to external validity, discuss how...
7.
Webster-Clark M, Keil A
Am J Epidemiol
. 2023 Feb;
192(7):1148-1154.
PMID: 36813295
Epidemiologic researchers generalizing or transporting effect estimates from a study to a target population must account for effect-measure modifiers (EMMs) on the scale of interest. However, little attention is paid...
8.
Webster-Clark M, Keil A, Robert N, Frytak J, Boyd M, Sturmer T, et al.
JAMA Oncol
. 2022 Oct;
PMID: 36227604
Importance: Delivery of adjuvant chemotherapy can differ substantially between trial and real-world populations. Adherence metrics like relative dose intensity (RDI) cannot capture the timing of modifications and mask differences in...
9.
Pak J, Lund J, Keil A, Westreich D, Sturmer T, Wohl D, et al.
Pharmacoepidemiol Drug Saf
. 2022 Aug;
31(12):1219-1227.
PMID: 35996832
Purpose: We aim to assess the reporting of key patient-level demographic and clinical characteristics among COVID-19 related randomized controlled trials (RCTs). Methods: We queried English-language articles from PubMed, Web of...
10.
Duchesneau E, Jackson B, Webster-Clark M, Lund J, Reeder-Hayes K, Napoles A, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Aug;
31(11):2079-2086.
PMID: 35984990
Background: Studies evaluating the effects of cancer treatments are prone to immortal time bias that, if unaddressed, can lead to treatments appearing more beneficial than they are. Methods: To demonstrate...